Financings

Advaxis Inc. generated $23 million in gross proceeds from the sale of 5.7 million shares plus warrants.

Aerie Pharmaceuticals Inc. plans to raise $68 million from its initial public offering (IPO).

Arrowhead Research Corp. closed a private offering for net proceeds of $60 million.

Aslan Pharmaceuticals Pte. Ltd. received $22 million in venture financing.

Celladon Corp. hopes to raise as much as $86.25 million from its IPO.

Cytrx Corp. closed a public offering for gross proceeds of about $25.9 million.

Egalet Ltd. filed to raise up to $69 million in an IPO.

G1 Therapeutics Inc. said it raised $12.5 million from a Series A financing.

Immatics Biotechnologies GmbH closed a $46.1 million Series D financing.

Macrogenics Inc. closed its IPO for gross proceeds of about $92 million

Portola Pharmaceuticals Inc. priced a public offering of 6.4 million shares at $23.75 apiece.

Ruthigen Inc. plans to offer 1.5 million shares in the price range of $12 to $14 in its IPO.

Sage Therapeutics Inc. generated $20 million from a Series B financing.

Seragon Pharmaceuticals Inc. raised $30 million in a Series A round.

Tekmira Pharmaceuticals Corp. priced a public offering for $30 million in gross proceeds.

Theravectys SAS closed a $20 million financing round.

Vital Therapies Inc. has filed to raise as much as $86.25 million from its IPO.

Xencor Inc. plans to raise $69 million from its IPO.

Deals

Argenta Discovery Ltd. extended its drug discovery agreement with Genentech Inc. for three years.

Astrazeneca plc is acquiring Spirogen plc for $200 million in cash and $240 million in potential milestones.

Auxilium Pharmaceuticals Inc. inked a deal with Vivus Inc. to market erectile dysfunction drug Stendra in the U.S. and Canada.

Dance Biopharm Inc. entered a joint venture with Harmony Asset for development of inhaled insulin in China.

Immunogen Inc. said Novartis AG licensed use of its antibody-conjugate technology.

Osiris Therapeutics Inc. will sell its culture-expanded mesenchymal stem cell business to Mesoblast Ltd.

Otsuka Holdings Co. Ltd. completed its acquisition of Astex Pharmaceuticals Inc. for $886 million.

Symphogen A/S has partnered with Open Monoclonal Technology Inc. to develop human therapeutic antibodies.

Zydus Cadila and Pieris AG entered an alliance to develop and commercialize Anticalin-based protein therapeutics.

. . . And More

Aastrom Biosciences Inc. will have about 4.4 million shares outstanding after a 1-for-20 reverse stock split.

Amarin Corp. plc shares fell after the Endocrinologic and Metabolic Drugs Advisory Committee recommended against approval of their lipid-lowering drug Vascepa in a supplemental indication.

Ampliphi Biosciences Corp. is developing bacteriophage therapy targeting C. difficile with the University of Leicester.

Antares Pharma Inc. received FDA approval of Otrexup (methotrexate) injection in rheumatoid arthritis.

Arena Pharmaceuticals Inc.’s partner Eisai Inc. is doubling the size of its Belviq (lorcaserin) sales force.

Coronado Biosciences Inc.’s shares tumbled on a Phase II failure of a drug candidate in Crohn’s disease.

Imaxio SA sold its genomics division to Hybrigenics SA for undisclosed terms.

Savient Pharmaceuticals Inc. has filed Chapter 11 voluntarily in the Bankruptcy Court for the District of Delaware, along with a motion seeking authorization to pursue a sale process.

Teva Pharmaceutical Industries Ltd. received FDA approval for a generic equivalent of Tobi (tobramycin) in cystic fibrosis.